ArticlePharmacognosy magazine2017
Rutamarin, an Active Constituent from
Article in Pharmacognosy magazine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- Compositional and Biofunctional Properties ofFoods (Basel, Switzerland) · 2026Article
- In Vitro Evaluation of Anti-Hemolytic and Cytotoxic Effects of Traditional Mexican Medicinal Plant Extracts on Human Erythrocytes and Cell Cultures.Life (Basel, Switzerland) · 2024Article
- The Cytotoxic Activity and Metabolic Profiling ofMolecules (Basel, Switzerland) · 2024Article
- Antimicrobial activity ofPeerJ · 2024Article
- Cytotoxic, Anti-Hemolytic, and Antioxidant Activities ofPlants (Basel, Switzerland) · 2023Article
- Review
- Phenolic Characterization Using cLC-DAD Analysis and Evaluation of In Vitro and In Vivo Pharmacological Activities ofAntioxidants (Basel, Switzerland) · 2022Article
- Furanocoumarins fromMolecules (Basel, Switzerland) · 2021Article
- Rutamarin: Efficient Liquid-Liquid Chromatographic Isolation fromMolecules (Basel, Switzerland) · 2020Article
- Cytotoxic effect of methanolic extract, alkaloid and terpenoid fractions ofResearch in pharmaceutical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
objectiveThe purpose of the study was to identify an active principle of MATERIALS AND
methodsThe methanol and fractionated extracts (hexane, chloroform, ethyl acetate, and water) of
resultsRutamarin exhibited remarkable cytotoxic activity against HT29 cells (IC
conclusionsThe present study describes rutamarin-induced apoptosis in the HT29 cell line for the first time and suggests that rutamarin has the potential to be developed as an anticancer agent. SUMMARY: Rutamarin was cytotoxic to HT29 colon cancer cells but exerted no damage to normal colon cellsRutamarin induced morphological and biochemical hallmarks of apoptosis in HT29 cellsRutamarin induced cell cycle arrest at the G0/G1 and G2/M checkpoints in a dose-dependent manner in HT29 cellsRutamarin activated caspases 3, 8, and 9 in a dose-dependent manner in HT29 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.